Retatrutide vs Semaglutide
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and Semaglutide (Ozempic). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | Semaglutide Ozempic, Wegovy |
|---|---|---|
| FDA Status | Phase 3 | FDA Approved |
| Category | Weight Loss | Weight Loss |
| Primary Use | Obesity and weight management | Type 2 diabetes and chronic weight management |
| Weight Loss % | 28.7% | 15% |
| Monthly Cost | $1,200 - $1,500/mo | $1,000 - $1,400/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 2.4mg weekly (Wegovy dose) |
| Frequency | Weekly | Weekly |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Phase 3 | Approved |
Key Differences
- 1Semaglutide is FDA-approved, while Retatrutide is currently phase 3.
- 2Retatrutide showed 28.7% average weight loss in trials compared to 15% for Semaglutide.
- 3Semaglutide is generally more affordable ($1,000 - $1,400/mo) compared to Retatrutide ($1,200 - $1,500/mo).
Which Is Better For...
Semaglutide
Those seeking an FDA-approved treatment with established safety data
Retatrutide
Maximum weight loss efficacy based on clinical trial data
Semaglutide
More budget-friendly option with lower monthly costs
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 | Eli Lilly |
| Semaglutide | $1,000 - $1,400/mo | FDA Approved | Novo Nordisk |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. They differ in FDA approval status, efficacy data, and cost.
In clinical trials, Retatrutide showed greater average weight loss (28.7%) compared to Semaglutide (15%). Individual results may vary.
Retatrutide typically costs $1,200 - $1,500/mo, while Semaglutide costs $1,000 - $1,400/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3). Semaglutide is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideSemaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Clinical trials demonstrated an average weight loss of 15% over ...
View Full Semaglutide GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and Semaglutide should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.